Skip to main content

Welcome to the Global liver health platform dedicated to healthcare professionals

Global Liver Health Forum 2024

DISCOVER THE LATEST UPDATES FROM THE 5TH GLOBAL LIVER HEALTH FORUM

Every year, the Global Liver Health Forum addresses the latest trends in liver healthcare with world-renowned scientific experts. Join this international network of healthcare professionals and elevate the quality of patient management.

WHAT IS IT ALL ABOUT?

The Global Liver Health Forum objective is to enhance knowledge on the identification and intervention strategies employed in the management of MAFLD/MASLD and the identification of the associated metabolic risks, it gathers experts across the globe to bring the latest perspectives on this important topic.

MAFLD in Focus: Unveiling Insights from China's RELIEF Study
Insights from APASL 2024
Metabolic and Toxic Liver Damage in focus
MANPOWER's Latest Breakthroughs Revealed

Shedding Light on Genomic, Metabolic, and Phenotypic Effects of Essential Phospholipids on HepaRG
Metabolic Comorbidities Unmasked
Redefining MASLD/MASH Impact

TEASER VIDEO

EXPERTS

Professor Lai Wei

PROFESSOR WEI LAI

Received his M.D. degree from Xuzhou Medical College in 1983 and Ph.D degree from Beijing Medical University in 1996. Prof. Wei Lai is a Professor of Hepatology and Medicine...

Professor Asad I. Dajani

PROFESSOR ASAD IZZIDDIN DAJANI

Obtained his Medical degree from the Faculty of Medicine, Cairo University in Egypt. He pursued his postgraduate studies and activities in internal medicine in the UK...

Professor Paola Luciani

PROFESSOR PAOLA LUCIANI

Paola Luciani is Full Professor of Pharmaceutical Technology at the University of Bern,
Switzerland since 2019 and Director of Study of the Bachelor in Pharmaceutical Sciences
since 2020.

Professor Marek Hartleb

PROFESSOR MAREK HARTLEB

Obtained his medical degree from the Medical University of Silesia in Katowice, Poland, in 1986, before pursuing a specialization in internal medicine and gastroenterology...

AGENDA

7th June 2024 12:45 PM - 1:45 PM

12:45-12:47

Welcome and Introduction

Dr A. Dajani

12:47-12:57

MAFLD in Focus: Unveiling Insights from China's RELIEF Study - Insights from APASL 2024

Professor Wei Lai

12:57-13:07

Metabolic and Toxic Liver Damage in focus - MANPOWER’s Latest Breakthroughs Revealed

Dr A. Dajani

13:07-13:17

Shedding Light on Genomic, Metabolic, and Phenotypic Effects of Essential Phospholipids on HepaRG

Professor P. Luciani

13:17-13:27

Metabolic Comorbidities Unmasked - Redefining MASLD/MASH Impact

Professor Hartleb

13:27-13:42

Q&A

13:42-13:45

Summary and closing remarks

Dr A. Dajani

DISCOVER MORE

TO WHAT EXTENT CAN HRQOL IMPACT CLINICAL OUTCOMES IN MAFLD?

Professor Lai Wei

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

ESSENTIAL PHOSPHOLIPIDS IN THE LIVER HEALTH LANDSCAPE

Professor Asad I. Dajani

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

MAFLD - THE IMPORTANCE OF EARLY IDENTIFICATION AND INTERVENTION

Professor Carmen Fierbinteanu

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

MAFLD - ASSOCIATED METABOLIC RISKS IN OBESITY AND DIABETES - INSIGHTS FROM CLINICAL PRACTICE

Professor Marek Hartleb

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

SIRIUS PROJECT - INSIGHTS FROM A POPULATION-WIDE LIVER DISEASE SCREENING PROGRAM IN SLOVAKIA

Professor Lubomir Skladany

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

TOOLS FOR EARLY DETECTION OF METABOLIC RISK IN MAFLD

Professor Jose D. Sollano Jr.

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

EARLY SCREENINF OF METABOLIC RISK - THE PHARMACISTS' PERSPECTIVE

Dr. Anamaria Cozma-Petruţ

DOWNLOAD THE SUMMARY

DOWNLOAD THE ONE PAPER

GET THE CONTENT

This website is intended for healthcare professionals only

Please click on 'healthcare professional' to continue to the website. If you are not a healthcare professional, please use the 'public' link for access to the public website.

Professor Marek Romuald Hartleb MD

speaker-3

Marek Hartleb is Head of the Department of Gastroenterology and Hepatology at the Medical University of Silesia in Katowice. He is also the Head of the Scientific Committee of the School of Medicine at the same university.

He obtained his medical degree from the Medical University of Silesia in Katowice, Poland, in 1986. He then pursued a specialisation in internal medicine and gastroenterology. In 1989, he was the recipient of a Fellowship of the French Ministry of Foreign Affairs and Laboratoires Fournier, which allowed him to spend two years working in the Splanchnic Haemodynamic Laboratory at Beaujon Hospital in Clichy, Paris, France. In 2005, he was appointed Professor of medicine.

Since 2014, he has been the President of the Hepatology Section of the Polish Gastroenterology Society. He also holds the post of Vice-President of the Polish Gastroenterology Society. He is the Editor-in-Chief of the national scientific journal Gastroenterologia praktyczna (Practical gastroenterology).

Norbert Stefan

Norbert Stefan is a trained endocrinologist and diabetologist. He is Holder of the W3 Heisenberg Professorship for Clinical and Experimental Diabetology at the University Hospital of Tübingen, Germany. He is also Head of the Department of Pathophysiology of Prediabetes at the Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Centre Munich.

Norbert Stefan focuses on the clinical-experimental approach to understand the pathogenesis of type 2 diabetes and its complications and to implement intervention strategies to prevent the disease. As a highlight of his research he precisely characterized metabolically healthy obesity and metabolically unhealthy normal weight in humans. A key finding of this research was the identification of the absence of fatty liver and mechanisms involved, more so than of visceral adiposity, as a determinant of metabolic health. Furthermore, he identified several hepatokines by which fatty liver impacts on the pathogenesis of type 2 diabetes and CVD. He is also conducting clinical trials to treat fatty liver and prevent type 2 diabetes. Norbert Stefan received several national and international scientific awards. He was a member of the executive committee of the German Diabetes Association and president of the 2015 Diabetes Congress of the German Diabetes Association. Norbert Stefan is presently Associate Editor of the scientific journal Diabetes and member of the International Advisory Board of The Lancet Diabetes & Endocrinology and received a Visiting Professorship from the Harvard Medical School.

^{Carmen Georgeta Fierbinteanu-Braticevici}

Professor, Head of chair of Internal Medicine II and Gastroenterology Head of Department Gastroenterology, University Emergency Hospital Bucharest

Doctor Carmen Fierbinteanu Braticevici MD, PhD, MPH has received her medical degree from The “Carol Davila” University of Medicine Bucharest in 1981, graduating at the top of her class. She did her residency in Internal Medicine at the same institution, and joined its Faculty in 1988 as Clinical Instructor. She was later promoted to Assistant Professor, Lecturer, Senior Lecturer and Professor in Gastroenterology and Internal Medicine at “Carol Davila” University of Medicine and Pharmacy, Bucharest, Medical Clinic II and Gastroenterology, University Hospital Bucharest. She holds board certifications in Internal Medicine, Gastroenterology, Diagnostic and Interventional Abdominal Ultrasonography, and has a Masters in Public Health. She serves as Division Chief in the Internal Medicine and Gastroenterology Department at The University Hospital Bucharest. Dr. Carmen Fierbinteanu served as a mentor to many generations of medical students and residents. She teaches Courses for the MD Program of the University, postgraduate courses for medical residents and has directed numerous student graduation theses. Every year she participates as evaluating Faculty in the Ministry Of Health’s Residency Selection and Board Certification Exams. She obtained her PhD in Cardiology with the thesis “Silent Myocardial Ischemia” which utilized stress echocardiography for detecting myocardial areas at risk in asymptomatic patients at a time when this was a novel concept. She authored Internal Medicine textbooks in Romania. As a member of EASL and AGA, she published numerous abstracts and articles. She had posters and oral presentations at international meetings. She led two national research projects. She is now implicated in International Projects as PI. She also functions as a research project evaluator for the Romanian Academy and the National Research Project VIASAN.

^{Professor Evgenii Ivanovich}

Leading Researcher research Center Saint Petersburg State Pediatric Medical University 12.2016 – up to date

Professor Military Medical Academy S.M. Kirov 2.2018 - up to date Head of the Department of Therapy Institute "Extreme Medicine" All- Russian Center for Emergency and Radiation Medicine. A.M. Nikiforova EMERCOM of Russia 2.2016 - 12.2017 professor Military Medical Academy S.M. Kirov 12.2008 - 10.2015

Alexander V. Nersesov

Alexander V. Nersesov, MD, ScD, Professor of Medicine – S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

Professor Nersesov is currently Head of the Department of Gastroenterology at the S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, and Invited professor of the Department of Propaedeutics, Gastroenterology and dietetics at the North-Western State Medical University named after I.I. Mechnikov, St Petersburg, Russia. He studied medicine at the Kazakh State Medical University and completed residency in internal medicine. Then Dr Nersesov went on to specialize in gastroenterology and immunology receiving his academic degrees of Candidate in Medical Sciences (1992), Doctor in Medical Sciences (1999), and academic ranks of Associate Professor and Full Professor (2003). Throughout his career Professor Nersesov has held professional appointment from Research Fellow (1992), Senior Research Fellow (1995) in the sequel and Head (2000) of the Clinical Department at the Research Center of Nutrition, Almaty, Kazakhstan to more recently Professor of Internal Medicine at the Kazakh State Medical Academy, Astana, Kazakhstan (2001-2008). Between 2001 and 2008 Professor Nersesov combined his academic career with state service at the Ministry of Health of the Republic of Kazakhstan as the Director of Medical Care and Prevention and the Counsellor for the Minister. In 2009 he moved to Japan as a Visiting Fellow in Hepatology at the National Health Organization Nagasaki Medical Center. On returning to Kazakhstan, Professor Nersesov started working for the National Research Institute of Cardiology and Internal Medicine as a Head of the Department of Gastroenterology and Hepatology (20092-2012), Chair of Gastroenterology, Hepatology and Endoscopy (2012-2019), and then moved to S.D. Asfendiyarov Kazakh National Medical University (since 2019). Professor Nersesov has professional affiliations with several professional organizations including European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), Asian Pacific Association for the Study of the Liver (APASL). Since 2007 he is the President of the Kazakh Association for the Study of the Liver (KASL). Professor Nersesov’s main clinical and research interests are chronic viral hepatitis? Autoimmine liver disease and liver cirrhosis complications. He is author and co-author of 163 publications in local and international journals, provides clinical supervision, serves as a principal investigator in clinical trials and the main organizer of local and international conferences on gastroenterology and hepatology in Kazakhstan.

^{Mrs Donna R. Cryer, JD}

Donna R. Cryer, JD, is the Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), the only patient-driven liver health nonprofit operating in the U.S. and Europe.

With an undergraduate degree from Harvard/Radcliffe Colleges and a Juris Doctorate from the Georgetown University Law Center, she has channelled her personal experience as a patient with inflammatory bowel disease and a 26-year liver transplant recipient into professional advocacy across a career in law, policy, consulting, public relations, clinical trial recruitment and nonprofit management.

At GLI, Mrs. Cryer has raised more than $5 million for liver health initiatives.

She developed a program featured by the White House on Solving Organ Shortage/Transplantation and numerous other successful programs. These include: the Cure Campaign, Advanced Advocacy Academy (A3), Liver Matters Blog, Liver Matters Health Policy Memo, the NASH Council, the Liver Cancers Council and the Pediatric and Rare Liver Diseases Council.

For almost a decade, Mrs. Cryer founded and led CryerHealth, a healthcare consultancy firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organisations and emerging technology firms on patient engagement in health information technology, drug discovery and clinical decision making.

Yiwen Shi

Yiwen Shi is a postdoc at Xinhua hospital affiliated to Shanghai Jiao Tong University School of Medicine. Dr. Shi’s background is clinical medicine and liver diseases. Her research interests are in nonalcoholic steatohepatitis, metabolic disorder diseases and viral hepatitis. She has participated in several NASH novel drugs clinical trials. She has published her work in the World Journal of Gastroenterology, Journal of Clinical and Translational Hepatology, Expert Opinion on Biological Therapy, Journal of Clinical Gastroenterology, and others. She presented and posted her research at conferences of European Association for the Study of the Liver and American Association for the Study of Liver Diseases. She obtained her doctors degree and masters degree in Capital Medical University in Beijing, China.

Prof. Chavdar Pavlov

speaker-4

Head of the Department of Therapy and Head of the Center for evidence based medicine, ‘Sechenov’ First Moscow State Medical University.

Prof Pavlov is Head of the Department of Therapy and Head of the Center for Evidence-Based Medicine at ‘Sechenov’ First Moscow State Medical University, Russia.

He is also editor for Cochrane Hepato-Biliary Group, providing guidance to authors and ensuring the quality of their work. Prof Pavlov is Vice President for foreign relations with the Russian Scientific Liver Society and Vice President of the Russian Scientific Society for the Study of Microbioma.

His research interests are fatty liver diseases.

^{Professor Jian-Gao Fan}

Dr. Jian-Gao Fan received his B.Sc. and M.Sc. degrees in 1994 at the Shandong Medical University, and his Ph.D. in 1997 at the Shanghai Second Medical University, respectively, both in China.

He was a Gastroenterologist and then also Associate Professor at Shanghai 1 st People’s Hospital from 1997 to 2007. He was a Visiting Scholar of Australian National University Medical School (Canberra, Australia) from 2007 to 2008. Then and up to now, he is Professor and Director of Center for Fatty Liver & Department of Gastroenterology at Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, and Principle Investigator of Shanghai Key Lab of Pediatric Gastroenterology and Nutrition.
Currently, he is Editor-in-Chief of Chinese Journal of Practical Hepatology, president of Committee on Fatty Liver Diseases, Chinese Physicians' Association, past-president for Shanghai Association for the Study of Liver Diseases, and past-chief of The China National Study Group on Fatty Liver and Alcoholic Liver Disease. He is a member of the editorial board of more than 20 journals, i.e., Clin Mol Hepatol., J Clin Trans Hepatol, J Dig Dis, HBPD INT, World J Gastroenterol, and also lots major journals’ peer-reviewers, i.e., Nat Rev Gastroenterol Hepatol, Gastroenterology, Hepatology, Arch Intern Med, Diabetes Care, J Hepatol.
His main research interests are in the fields of metabolic syndrome and chronic liver diseases. He has published over 700 peer-reviewed academic papers (including over 127 articles in SCI journals as the first and/or correspondent author, i.e, Nat Rev Gastroenterol Hepatol, Hepatology, J Hepatol, Aliment Pharmacol Ther., Cell Mol Gastroenterol Hepatol.,Cancer Lett, EBioMedicine, Liver Int, Exp Mol Med, and 5 book chapters in English) with H-index 51, and 19 books as editor-in-chief, i.e, 1 st & 2 nd Edition, Fatty Liver Disease in China People’s Medical Publishing House. He was co-chairman of the Biennial Shanghai International Forum on Digestive Diseases between 2010-2021, and invited speaker in over 20 countries and regions.

Representative Publications
[1] Ren TY, Fan JG*. What are the clinical settings and outcomes of lean NAFLD?. Nat Rev Gastroenterol Hepatol 2021;18(5):289-290. IF:46.802
[2] Zhao ZH#, Wang ZX#, Zhou D, Han Y, Ma F, Hu Z, Xin FZ, Liu XL, Ren TY, Zhang F, Xue Y, Cui A, Liu Z, Bai J, Liu Y, Cai G, Su W, Dai X, Shen F, Pan Q, Li Y*, Fan JG*.Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene. Cell Mol Gastroenterol Hepatol. 2021 May 11:S2352-345X(21)00095-3. doi: 10.1016/j.jcmgh.2021.05.006. IF:9.225
[3] Liu XL, Pan Q, Cao HX, Xin FZ, Zhao ZH, Yang RX, Zeng J, Zhou HP, Fan JG*. Lipotoxic Hepatocyte-Derived Exosomal miR-192-5p Activates Macrophages via Rictor/Akt/FoxO1 Signaling in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;72(2):454-469. IF:17.425
[4] Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, Cao HX, Chen ML, Xu L, Chen JN, Cao Y, Zhang RN, Xu LM, Fan JG*. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis. Aliment Pharmacol Ther. 2019;50(1):93-102. IF: 7.731
[5] Zhao ZH, Xin FZ, Xue YQ, Hu ZM, Han YM, Ma FG, Zhou D, Liu XL, Cui AY, Liu ZS, Liu YX, Gao J, Pan Q, Li Y*, Fan JG*. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats. Exp Mol Med. 2019; 51(9):103. IF:5.418, 8.718
[6] Zhou D, Chen YW, Zhao ZH, Yang RX, Xin FZ, Liu XL, Pan Q, Zhou H*, Fan JG*. Sodium butyrate reduces high fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018; 50(12):157. IF:5.584
[7] Fan JG*, Kim SU, Wong Vincent WS*. New Trends on Obesity and NAFLD in Asia. J Hepatol, 2017; 67:862-873. IF: 14.911

Professor Gert Fricker MD, PhD

Gert Fricker is Professor at the Institute of Pharmacy and Molecular Biotechnology in the Faculty of Biosciences, University of Heidelberg, Germany.

He studied chemistry and medicine at the University of Freiburg, Germany, completing his PhD in 1986. He then worked as a Post-Doc in the Clinical Pharmacology Department, University Hospital Zurich, Switzerland. In 1988 he became research scientist at Sandoz Pharma AG, Basel, Switzerland. In the Drug Delivery Systems Department he studied mechanisms of drug permeation across barrier tissues.

In 1995 he was appointed as Professor at the University of Heidelberg, becoming chair of Pharmaceutical Technology in 2002.

In addition to his university affiliation, Prof Fricker is Head of the Biopharmacy and Analytics Technology Transfer Center in Heidelberg, a service centre for the pharmaceutical Industry.

In 2016, he set-up HeiDelTec GmbH a spin-off company from the University of Heidelberg offering novel oral peptide drug delivery solutions.

His main research interests are the permeation of drugs across barrier tissues with particular emphasis on the intestine and blood brain barrier as well as the development of drug targeting systems with colloidal drug carriers.

Prof. Zobair M. Younossi

speaker-1

President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus, United States.

Prof Younossi is the President of Inova Medicine, Inova Health System and the Chairman and Professor of Medicine, Inova Fairfax Medical Campus. He is also the Chairman of Clinical Research, Inova Health System.

Prof Younossi earned his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York (Alpha Omega Alpha, 1989), and completed his residency in internal medicine as well as a fellowship in gastroenterology and hepatology at Scripps Clinic and Research Foundation in La Jolla, California. During his residency and fellowship, he earned his Master of Public Health degree from San Diego State University (SDSU) School of Public Health in San Diego, California, being awarded both the Hanlon Award and Outstanding Student Award for SDSU. He then served as the Staff Hepatologist and Senior Researcher at the Cleveland Clinic Foundation, Cleveland, Ohio (1995– 2000). In 2000, Prof Younossi joined Inova Health System to establish the Center for Liver Diseases.

Prof Younossi is an internationally known hepatologist who has pioneered research in NAFLD and has been a leader in the field of patient-reported outcomes, economic assessment and outcomes research in liver disease. He is the Chair of Global NASH Council and the Global Liver and NASH Registries. His research in both NAFLD and outcomes research is extensively cited and he is a highly sought-after speaker for national and international scientific meetings.

Prof Younossi specializes in hepatology and gastroenterology and has authored over 600 articles, 3 books, 6 journal supplements and has delivered over 430 faculty lectures in national and international meetings. Prof Younossi has also served as the co-editor of Liver International, Associate Editor of Journal of Hepatology and the editorial board of a number of important medical journals. He has represented the American Association of Liver Disease and American Gastroenterological Association at different congressional meetings.

^{Prof. Jörn M. Schattenberg}

speaker-2

Director of the Metabolic Liver Research Program, University Medical Center Mainz, Germany.

Prof Schattenberg is the Director of the Metabolic Liver Research Program and the Clinical Liver Research Unit at the University Medical Center Mainz, Germany.

He is a full professor of Medicine and serves on the Editorial Board of Hepatology and Alimentary Pharmacology & Therapeutics. He is a member of the executive committee of the LITMUS consortium for the validation of biomarkers in NASH.

His research interests are on clinical and experimental aspects of metabolic and toxic liver injury, the development of therapeutic intervention and novel biomarkers in NASH

^{Prof. Huiying Rao}

speaker-5

Chief physician, professor, and assistant director of Peking University Hepatology Institute. She is also deputy director of the scientific research department and deputy director of the clinical trial institution in Peking University People’s Hospital.

Prof Rao is the Chief physician and professor, and assistant director of Peking University Hepatology Institute, China. She is also the deputy director of the scientific research department and deputy director of clinical trial institution in Peking University People’s Hospital, China.

Prof Rao carried out her medical and research training at Peking University Health Science Center before being appointed as lecturer in infectious diseases in 2006.

Her research interests are in clinical management of viral hepatitis, fatty liver diseases and cirrhosis

^{Professor Yi Min Mao MD, PhD}

Professor Mao MD, PhD

Prof Mao is Director of the Shanghai Research Center for Fatty Liver Disease and Chief Physician in the Renji Hospital, Department of Gastroenterology. Professor at the Shanghai Jiao Tong University School of Medicine, he has 30 years of clinical experience in the management of liver diseases, especially in drug-induced liver injury (DILI) and NAFLD.

Prof. Mao has conducted more than 200 clinical trials as principal investigator in the field of gastrointestinal and liver diseases in China. He is also the leading PI of National Eleven-Five and Twelve-Five Projects for building clinical and translational research platforms for liver disease in China. He has published more than 200 papers in well-considered international journals such as Gastroenterology, Hepatology, Liver International, etc.

He is currently a member or president of numerous national and international associations including: the DILI Working Group of the Council for International Organizations of Medical Science (CIOMS), the American Association for the Study of Liver Diseases, Chinese Society of Hepatology, Chinese Medical Association and more.

Prof. Bogusław Okopień

speaker-3

Head of the Department of Internal Medicine and Clinical Pharmacology at the Medical University of Silesia and Medical Director at NZOZ Terapia Optima in Katowice.

Prof Okopień is Head of the Department of Internal Medicine and Clinical Pharmacology at the Medical University of Silesia and Medical Director at NZOZ Terapia Optima in Katowice, Poland.

Prof Okopień has achieved specializations in Internal Medicine, Clinical Pharmacology and Hypertensiology. He is a member of the Polish Pharmacological Society, Polish Society of Clinical Pharmacology & Therapy, Polish Society of Internal Medicine, Society of Monitored Therapy, New York Academy of Sciences, Polish Society of Insurance Medicine, Polish Society for the Research of Atherosclerosis, and the International Atherosclerosis Society.

Prof Okopień has received a medal for the National Education Committee, the 100th Anniversary of the Polish Society of Internal Medicine and the Badge of Merit for the Silesian Medical University.

He is the author of 587 scientific papers and his main research interest is in the field of pharmacology, where his team have received several awards: the 1st degree of the Minister of Health twice; the 2nd degree award of the Rector of ŚAM; and the 1st degree Rector of SUM.

ALEXANDER V. NERSESOV

speaker-3

Alexander V. Nersesov, MD, ScD, Professor of Medicine – S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

Professor Nersesov is currently Head of the Department of Gastroenterology at the S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, and Invited professor of the Department of Propaedeutics, Gastroenterology and dietetics at the North-Western State Medical University named after I.I. Mechnikov, St Petersburg, Russia. He studied medicine at the Kazakh State Medical University and completed residency in internal medicine. Then Dr Nersesov went on to specialize in gastroenterology and immunology receiving his academic degrees of Candidate in Medical Sciences (1992), Doctor in Medical Sciences (1999), and academic ranks of Associate Professor and Full Professor (2003). Throughout his career Professor Nersesov has held professional appointment from Research Fellow (1992), Senior Research Fellow (1995) in the sequel and Head (2000) of the Clinical Department at the Research Center of Nutrition, Almaty, Kazakhstan to more recently Professor of Internal Medicine at the Kazakh State Medical Academy, Astana, Kazakhstan (2001-2008). Between 2001 and 2008 Professor Nersesov combined his academic career with state service at the Ministry of Health of the Republic of Kazakhstan as the Director of Medical Care and Prevention and the Counsellor for the Minister. In 2009 he moved to Japan as a Visiting Fellow in Hepatology at the National Health Organization Nagasaki Medical Center. On returning to Kazakhstan, Professor Nersesov started working for the National Research Institute of Cardiology and Internal Medicine as a Head of the Department of Gastroenterology and Hepatology (20092-2012), Chair of Gastroenterology, Hepatology and Endoscopy (2012-2019), and then moved to S.D. Asfendiyarov Kazakh National Medical University (since 2019). Professor Nersesov has professional affiliations with several professional organizations including European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD), Asian Pacific Association for the Study of the Liver (APASL). Since 2007 he is the President of the Kazakh Association for the Study of the Liver (KASL). Professor Nersesov’s main clinical and research interests are chronic viral hepatitis? Autoimmine liver disease and liver cirrhosis complications. He is author and co-author of 163 publications in local and international journals, provides clinical supervision, serves as a principal investigator in clinical trials and the main organizer of local and international conferences on gastroenterology and hepatology in Kazakhstan.

Professor Mohammed Eslam

speaker-3

Leading Professor at Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, Australia.

Professor Eslam is an Associate Professor of hepatology at the Storr Liver Centre, University of Sydney. He heads the fatty liver and genomics groups at Storr Liver Centre and the International Liver Genetics Consortium that led to the identification of genetic and epigenetic factors that impact hepatic steatosis, inflammation and fibrosis. He led the international consensus for redefining fatty liver disease. Professor Eslam undertakes basic and clinical research on MAFLD, hepatitis C, liver cancer and hepatic fibrosis and is the author of more than 120 publications. He is on the Editorial Board of Liver International, Clinical and Experimental Medicine, the Journal of Clinical andTranslational Hepatology and World Journal of Hepatology.

Professor Leonid Lazebnik

speaker-3

A. I. Leading Professor at Evdokimov, Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia. President of the Gastroenterology Scientific Society of Russia.

Professor Lazebnik is a Professor of the Department of Outpatient Internal Medicine at the Moscow State University of Medicine and Dentistry. In addition to his teaching, Professor. Lazebnik holds a number of senior roles, including Editor-in-Chief of the Experimental and Clinical Gastroenterology journal, President of the Gastroenterological Scientific Society of Russia and Vice-President of the Russian Scientific Society of Internal Medicine. As a member of the Guidelines Committee of the World Gastroenterology Organization, Professor Lazebnik has played an instrumental role in shaping the way patients are treated and managed.

Miss Alexandra Fulford

speaker-3

Digital & Social Media Strategist & Reverse Mentor

Alexandra Fulford is a digital and social media strategist and reverse mentor,specialised in the healthcare industry and digital transformation. Her areas of specialty are digital transformation, digital and socialmedia strategy and implementation, social media processes,guidelines, training and implementation and global to loca limplementation. She is also an experienced reverse mentor for C Suite executives, and has developed reverse mentoring programmes for pharma companies to help drive digital and strategic transformation.

Dr Asad Izziddin Dajani

speaker-3

Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital in Sharjah.

Doctor Dajani is a Consultant Gastroenterologist & Hepatologist at Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital in Sharjah, United Arab Emirates. He was instrumental in establishing the Endoscopy service at the Kuwait and Al Qassimi Hospitals in Sharjah, United Arab Emirates.
Doctor Dajani has many publications in the field of his work and is also a member of the editorial board for many reputed journals of gastroenterology and Chairman and Moderator for many of the local Emirates Medical Associations, regional and international symposia and conferences.

Learn the key topics that GLHF speakers will talk about for the upcoming 7^th of October session.

Experience and Education:
Dr Asa’d Izziddin Dajani obtained his Medical degree from the Faculty of Medicine, Cairo University in Egypt. He pursued his postgraduate studies and activities in internal medicine in the UK, USA and Austria.
Dr Dajani has an experience of having worked at various hospitals in Egypt, Kuwait and Vienna, gaining wide experience in his field. In 1984, he relocated to UAE, where he was instrumental in establishing the Endoscopy service at the Kuwait Hospital in Sharjah.
Dr Dajani regularly attends local, regional as well as international conferences and shares his expertise with his peers all over. He is regularly invited as a guest lecturer to various medical conventions, institutes, and pharmaceutical sponsored meetings locally, regionally and interna- tionally. Dr Dajani has many publications to his credit in reputed local as well as international Medical journals. He has also presented to many conferences and seminars worldwide.

Jose D. Sollano, Jr., is Professor of Medicine at the University of Santo Tomas (UST) Faculty of Medicine and Surgery, Manila, the Philippines. He was also a Visiting Professor at the University of Arizona - Tucson School of Medicine.

After finishing his Gastroenterology Fellowship training at UST, he proceeded to train in Hepatology, ultrasound and interventional techniques with Prof Kunio Okuda at Chiba University, Japan and in Therapeutic Endoscopy with Prof Nib Soehendra at the University of Hamburg, Germany. He also had Visiting Fellowships in Gastroenterology at the Cleveland Clinic in Ohio and at the Mayo Clinic in Minnesota.

He has authored/co-authored 5 book chapters and several original scientific articles in peer-reviewed journals. He is also a reviewer and/or member of the Editorial Board of several international periodicals in Gastroenterology, Endoscopy and Hepatology.

He has been Faculty and/or Convenor of a number of Asian-Pacific Consensus Guidelines, including those on Chronic Hepatitis B, Chornic Hepatitis C, NAFLD, Portal Hypertension, Non Variceal Upper GI Bleeding and Inflammatory Bowel Diseases. In 1990, he founded the Inflammatory Bowel Disease (IBD) Club of the Philippines and in 2019, he co-organized the Crohn's and Colitis Philippines (C&Cph), a national IBD Patient Support Group.

Prof. Sollano is a Past President of the Asia Pacific Association for the Study of the Liver (APASL). He is also Past President of the Hepatology Society of the Philippines, Philippine Society of Gastroenterology and Digestive Endoscopy, as well as, the Philippine College of Physicians. He is a member of the Chronic Hepatitis B Global Guidelines Task Force of the World Gastroenterology Organization (WGO), member of the APAGE Research Fund Committee and is a Fellow of the American College of Physicians.

Dr. An Wei is Chief of the Department of Cell Biology Capital Medical University, Beijing, China. He is also the Head of Beijing Key Laboratory of Liver Protection and Regeneration. He received his MD degree in 1990 and then worked as postdoc in University of Erlangen, Germany, and Institute for Biomedical Research, CSIC, Madrid Spain. In 1999 he was promoted to professor and assigned as Head of Dept. Cell Biology. The research work of Prof. An focuses on hepatic protection associated with mitochondrial mechanism, of which, he has been awarded more 10 grants from the Chinese National Natural Scientific Foundation and published 70 internationally recognized peer-reviewed papers as first/corresponding author. Prof. An serves as a former president of Chinese Society of Medical Cell Biology.

Importance of hepatic membrane protection against NAFLD/NASH
What will you learn:
• NAFLD/NASH is becoming the most prevalent chronic liver disease worldwide and yields to heavy burden globally.
• Hepatic protection from cell injury or death is closely related with cell membrane as well as mitochondrial functionality.
• Pharmaceutical treatment for patients with NAFLD/NASH with supplementing components of cell membrane such as polyene phosphatidylcholine proves effective at least on preservation of cell membrane stability and balance of mitochondrial dynamic.

Professor Lu is Chief of the Department of Gastroenterology, Chief Physician, Doctor Tutor of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. He mainly engaged in basic and clinical research of digestive diseases, especially hepatobiliary diseases.

Professor Lu is currently the vice Chairman of the Hepatology Society of Chinese Medical Association, Chairman of Shanghai Hepatology Society, Member of the Digestion Society of Chinese Medical Doctor Association, Member and Secretary of the Digestion Society of Shanghai Medical Doctor Association.

Professor Lu is the chief editor of 6 monographs. An associate editor or a member of the editorial board of 28 journals, and a peer-reviewer for several other major journals. His main research interests are in fatty liver prevention and treatment, and non-invasive diagnosis and clinical intervention of liver fibrosis, etc. He had published over 140 SCI papers, included Hepatology, J Hepatology, Cell Res, Clin Translat Gastroenterol, J Gastroenterol Hepatol and Hepatol Res, etc.

An overview of recent drug progress of NASH treatment
What will you learn:
• NASH is an inflammatory type of NAFLD and is associated with disease progression.
• Current pharmacological or adjuvant drugs interventions for NASH.
• Pharmacological drugs under development bring challenges and hopes.

Learn the key topics that GLHF speakers will talk about for the upcoming 13^th of May session in only 1 minute!

Learn the key topics that GLHF speakers will talk about for the upcoming 13^th^ of May session in only 1 minute!

Professor Lai Wei

PROFESSOR WEI LAI

Received his M.D. degree from Xuzhou Medical College in 1983 and Ph.D degree from Beijing Medical University in 1996. Prof. Wei Lai is a Professor of Hepatology and Medicine and Director of the Hepatopancreatobiliary Center at Beijing Tsinghua Changgung Hospital, Tsinghua University, China. His current research interests involve NAFLD, hepatocellular carcinoma, and antiviral treatment of hepatitis B. Prof. Wei has served as the President of the Chinese Society of Hepatology (2012–2015) and aided to develop the Chinese Guidelines for the Management of Hepatitis B; Management, Diagnosis and Prevention of Hepatitis C Virus Infection; and Management and Diagnosis of NAFLD. In addition, Prof. Wei will be President of the Asian-Pacific Association for the Study of the Liver (APASL) in 2025 and contribute to the WHO and APASL hepatitis C guidelines.

PROFESSOR ASAD IZZIDDIN DAJANI

PROFESSOR ASAD IZZIDDIN DAJANI

Obtained his Medical degree from the Faculty of Medicine, Cairo University in Egypt. He pursued his postgraduate studies and activities in internal medicine in the UK, USA and Austria. Prof. Asad I. Dajani is a Consultant Gastroenterologist and Hepatologist at Asad Dajani Specialized Clinic, with affiliation to Medcare and Saudi German hospital, Sharjah, United Arab Emirates. He was instrumental in establishing the Endoscopy service at the Kuwait and Al Qassimi Hospitals in Sharjah, United Arab Emirates. Prof. Dajani has many publications in the field of his work and is also a member of the editorial board for many reputed journals of gastroenterology, and Chairman and Moderator for many of the local Emirates Medical Associations, regional and international symposia and conferences.

PROFESSOR PAOLA LUCIANI

PROFESSOR PAOLA LUCIANI

Paola Luciani is Full Professor of Pharmaceutical Technology at the University of Bern, Switzerland since 2019 and Director of Study of the Bachelor in Pharmaceutical Sciences since 2020.

Prof. Luciani is external Specialist for Pharmaceutical Quality in the Human and Veterinary Medicines Expert Committee of the Agency Council of Swissmedic, the Swiss Agency for Therapeutic Products and she was recently elected expert of the NANO (Nanomedicine) Working Group by the European Pharkacopoeia, EDQM. She is an invited member of: the Scientific Advisory Council of the Phospholipid Research Center, Heidelberg; the Steering Committee of the Stem Cell and Regenerative Medicine Platform (UniBern); the Sounding Board of the Multidisciplinary Center for Infectious Diseases (UniBern) among others, and member of the Controlled Release Society, Swiss Chemical Society and the Swiss Academy of Pharmaceutical Sciences. Prof. Luciani has been named Emerging Investigator 2017 by the Royal Society of Chemistry.

Prof. Luciani leads a research group in Pharmaceutical Technology and Drug Delivery working on the design and characterization of lipid-derived and bio-inspired drug delivery systems for the treatment and diagnosis of chronic multifactorial diseases, such as fibrosis, endometriosis and inflammatory diseases.

PROFESSOR MAREK HARTLEB

PROFESSOR MAREK HARTLEB

Obtained his medical degree from the Medical University of Silesia in Katowice, Poland, in 1986, before pursuing a specialization in internal medicine and gastroenterology. In 1989, he was the recipient of a fellowship from the French Ministry of Foreign Affairs and Laboratoires Fournier, which allowed him to spend two years working in the Splanchnic Haemodynamic Laboratory at Beaujon Hospital in Clichy, Paris, France. In 2005, he was appointed as the Professor of Medicine. Prof. Hartleb is an author of two-volume book entitled “Hepatology Secrets” published in 2022. Since 2021, Prof. Hartleb holds the post of President of the Polish Gastroenterology Society.

PROFESSOR LUBOMIR SKLADANY

PROFESSOR LUBOMIR SKLADANY

Received his M.D. degree from Faculty of Medicine, Comenius University, Špitálska, Bratislava in 1988 and Ph.D degree from Slovak Medical University in Bratislava, Limbová, in 2002. Prof. Skladany is Head of 2nd Department of Internal Medicine with HEGITO Liver & Tansplant Unit at F.D. Roosevelt University Hospital in Banska Bystrica, Slovakia. He works as an Assistant Professor at the 2nd Department of Internal Medicine of Pavol Jozef Šafárik University (UPJŠ) Faculty of Medicine in Košice, and Slovak Medical University Bratislava, Slovakia. Prof. Skladany is one of the leading Slovak Hepatologists and Gastroenterologists, and is the Lead Hepatologist of the Transplant Centre. Prof. Skladany was heavily involved in launching the liver transplant program at F.D. Roosevelt University Hospital, Banska Bystrica, Slovakia. He is a member of major international professional associations, including the European Association for the Study of the Liver (EASL), and American Association for the Study of Liver Diseaes (AASLD). He is the founder of a specialized division of hepatology, gastroenterology and liver transplantation (HEGITO), which provides care for patients with the whole spectrum of liver diseases including before and after liver transplantation. He served as President of the Slovak Hepatological Society and is the member of the governing board of the Slovak Transplant Society.

PROFESSOR JOSE D. SOLLANO JR.

PROFESSOR JOSE D. SOLLANO JR.

Graduated from the University of Santo Tomas, Philippines, and is now a Professor in the Faculty of Medicine and Surgery, specializing in gastroenterology and hepatology. In 1990, Prof. Sollano established the Inflammatory Bowel Disease Club of the Philippines and has since pioneered the study and understanding of IBD in the country. He has published peer-reviewed articles in the fields of his major professional interests, including IBD, gastroesophageal reflux disease, chronic hepatitis B and C, hepatocellular carcinoma and therapeutic endoscopy. He has also been involved in the development of various Asia-Pacific and National Clinical Practice Guidelines. Prof. Sollano is a Past President of the AsiaPacific Association for the Study of the Liver (APASL) and has also worked with several other organizations, including the Coalition to Eradicate Viral Hepatitis in the Asia Pacific (CEVHAP) in the Philippines, and is a member of the Chronic Hepatitis B Global Guidelines Task Force of the World Gastroenterology Organization (WGO).

DR. ANAMARIA COZMA-PETRUŢ

DR. ANAMARIA COZMA-PETRUŢ

Is an Associate Professor in the Department of Bromatology, Hygiene and Nutrition of the Faculty of Pharmacy at the Iuliu Haţieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. In 2009, Dr. Cozma-Petruţ obtained her bachelor’s degree in Pharmacy from the Iuliu Haţieganu University of Medicine and Pharmacy. She also received a PhD in Medical Sciences, Pharmacy domain, in 2013, following four years of research on modulation of cow and goat milk fat composition conducted at the Iuliu Haţieganu University of Medicine and Pharmacy and the Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), Clermont-Ferrand/Theix, France. In 2013, Dr. Cozma-Petruţ obtained national certification as a Specialist Pharmacist in the specialty of pharmaceutical laboratory. Her teaching interests include food chemistry and hygiene, healthy foods, food supplements, nutrition in the lifecycle, precision nutrition, medical nutrition therapy, health promotion and therapeutic patient education. Her main research interests are in the fields of development of functional foods, one health approach, evaluation of dietary patterns among various population groups and assessment of the role of diet in the prevention and management of diseases (obesity, cancer, gastrointestinal and liver disorders).